⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599397 | 1.00 | — | — | |
| SCHEMBL4040646 | 0.85 | PKM (0.36) | — | |
| SCHEMBL4034941 | 0.83 | PKM (0.35) | — | |
| SCHEMBL29751151 | 0.83 | — | — | |
| SCHEMBL14932913 | 0.83 | — | — | |
| SCHEMBL20115811 | 0.80 | — | — | |
| SCHEMBL1939702 | 0.77 | PKM (0.35) | — | |
| SCHEMBL4038153 | 0.74 | DPP4 (0.32) | — | |
| SCHEMBL3386097 | 0.74 | PKM (0.33) | — | |
| SCHEMBL3336213 | 0.73 | GRIN1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115972693-B | Tipping-resistant metal ceramic cutter and preparation method thereof | 江苏伊斯达尔精密科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-115972693-A | Tipping-resistant metal ceramic cutter and preparation method thereof | 江苏伊斯达尔精密科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| EP-4717316-A2 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | AbbVie Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250170263-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2016094505-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158218-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9227963-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9187472-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8889675-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |